Free Trial
NASDAQ:RANI

Rani Therapeutics Q3 2026 Earnings Results & Report

Rani Therapeutics logo
$0.53 +0.00 (+0.21%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$0.52 -0.01 (-1.58%)
As of 11/13/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rani Therapeutics beat analyst expectations on both earnings and revenue in its Q3 2026 results, released November 9, 2026. The company reported EPS of -$0.04 versus the -$0.0475 consensus estimate, while revenue of $1.71 million topped the $1.28 million estimate by $427.00 thousand.

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
After Market Closes
Conference Call
4:00 PM ET

Rani Therapeutics EPS Results

Actual EPS
-$0.04
Consensus EPS
-$0.0475
Beat/Miss
Beat by +$0.0075
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Rani Therapeutics Revenue Results

Actual Revenue
$1.71 million
Expected Revenue
$1.28 million
Beat/Miss
Beat by +$427.00 thousand
YoY Revenue Growth
N/A

Rani Therapeutics Q3 2026 Earnings FAQ

Rani Therapeutics (NASDAQ:RANI) reported earnings of -$0.04 per share for Q3 2026, beating the consensus estimate of -$0.0475. The report was announced on Monday, November 9, 2026.

Rani Therapeutics reported revenue of $1.71 million for Q3 2026, against a consensus estimate of $1.28 million.

Rani Therapeutics Earnings Headlines

A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.tc pixel
Rani Therapeutics (RANI) Expected to Release Earnings on Thursday
See More Rani Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Rani Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rani Therapeutics and other key companies, straight to your email.

About Rani Therapeutics

Rani Therapeutics (NASDAQ:RANI) is a clinical-stage biotherapeutics company developing technology to deliver biologic medicines orally. Its RaniPill platform is designed to transport drugs such as peptides and antibodies through the digestive system and release them into the intestinal wall, with the goal of offering an alternative to injections.

Founded in 2012 and based in San Jose, California, the company develops its delivery platform and evaluates it with drug candidates and potential partner medicines. Rani’s work focuses on addressing challenges that have traditionally made many biologic drugs difficult to administer by mouth.

View Rani Therapeutics Profile